Nitric oxide regulates matrix metalloprotease-13 expression and activity in endothelium  by Zaragoza, Carlos et al.
Kidney International, Vol. 61 (2002), pp. 804–808
Nitric oxide regulates matrix metalloprotease-13 expression
and activity in endothelium
CARLOS ZARAGOZA, MILAGROS BALBI´N, CARLOS LO´PEZ-OTI´N, and SANTIAGO LAMAS
Centro de Investigaciones Biolo´gicas, Instituto “Reina Sofı´a” de Investigaciones Nefrolo´gicas, Consejo Superior de
Investigaciones Cientı´ficas, Madrid, and Departamento de Bioquı´mica y Biologı´a Molecular, Facultad de Medicina,
Instituto Universitario de Oncologı´a, Universidad de Oviedo, Oviedo, Spain
Nitric oxide regulates matrix metalloprotease-13 expression and The effect of NO on MMP expression and/or activity is
activity in endothelium. summarized in Table 1.
Background. Matrix metalloproteinases (MMPs) are synthe- Matrix metalloproteinases, also called matrixins orsized in response to diverse stimuli including cytokines, growth
MMPs, are proteolytic zinc-dependent endopeptidasesfactors, hormones, and oxidative stress.
involved in the degradation of extracellular matrix com-Methods. Bovine aortic endothelial cells (BAEC) were stimu-
lated with nitric oxide (NO) and MMP-13 expression and activity ponents. Depending on the substrate, they can be grouped
was assayed. into four categories: collagenases, gelatinases, stromely-
Results. NO transcriptionally regulated matrix metallopro-
sins and membrane-type metalloproteinases. MMPs areteinase-13 (MMP-13) expression in BAEC, while the cGMP
synthesized by a wide variety of cell types, includinganalog 8Br-cGMP mimicked the effect of NO. In addition NO
also stimulated the proteolytic processing of MMP-13 from the fibroblasts, chondrocytes, epithelial cells, inflammatory
pro-enzyme to the final active form in a dose dependent manner. cells, and endothelial cells [19].
Conclusion. NO transcriptionally regulates MMP expression Endothelial cells synthesize MMPs by means of differ-and activity in the vascular endothelium. This effect of NO may
ent stimuli [20, 21]. MMP activity has been associatedbe of pathophysiological importance in the context of angiogen-
with diverse angiogenic-mediated responses such as in-esis, inflammation or atherogenesis.
flammation, wound healing, tumor invasion, ovulation,
and atherosclerosis [22, 23]. In addition, endothelial cells
Angiogenesis is an invasive process that requires endo- synthesize MMPs as result of their interaction with im-
thelial cell migration to the new blood vessels, and thus mune cells like monocytes and T lymphocytes. De novo
extracellular matrix remodeling is a pre-requisite in which expression of gelatinase B (MMP-9), increased intersti-
matrix metalloproteinases are involved [1]. Among the tial collagenase (MMP-1) and stromelysin (MMP-3), and
different factors implicated, vascular endothelial growth activated gelatinase A (MMP-2), are thought to be medi-
factor (VEGF) strongly induces angiogenesis of endo- ated by CD40/CD40 direct signaling [24, 25].
thelial cells, and although the intracellular mechanisms This study shows that exogenously administered NO
lying downstream the VEGF signaling are not fully under- promotes an increase in the MMP-13 steady-state level
stood, several lines of evidence suggest that nitric oxide mRNA of bovine aortic endothelial cells (BAEC), ac-
(NO) is an important effector. First, exogenous adminis- companied by an increase in MMP-13 processing and
tration of NO promotes endothelial cell proliferation and activity. The process is regulated in part by the NO/cyclic
migration [2]. Second, the pharmacological inhibition of 3,5-guanosine monophosphate (cGMP)/protein kinase
endothelial NO production has the opposite effect [3]. G (PKG) axis. Physiological implications are discussed.
Finally, in vivo angiogenesis is accompanied by vasodila-
tion [4].
METHODSHow does NO mediate VEGF-induced angiogenesis
of endothelial cells? One possible explanation relies on Cells and reagents
the effect of MMP expression and/or activity; however, Bovine aortic endothelial cells were incubated as pre-
there are no definitive data pointing in a major direction. viously described [26]. Cell culture supplies were from
Falcon (Beckton-Dickson, Le Point de Claix, France),
calf serum was from BioWhittaker (Verviers, Belgium),Key words: vascular remodeling, MMP, angiogenesis, nitrosative stress,
NO, inflammation. cell culture gelatin and antibiotics were from Sigma
(St. Louis, MO, USA). Reverse transcribed-polymerase 2002 by the International Society of Nephrology
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Table 1. Effect of nitric oxide (NO) on matrix metalloproteinase (MMP) expression and/or activity
MMP Tissue/cell type Species Effect Reference
Collagenase Articular chondrocytes Bovine Activation [5]
Collagenase Cartilage Human, bovine Activation [6]
MMP-1 Cartilage Dog Increase levels [7]
MMP-2 Rheumatoid synovial cells Human Increase levels [8]
MMP-2 Fibrosarcoma epithelial cancer Human Release inhibition [9]
MMP-2 Carotid artery Rabbit Activation [10]
MMP-2 Adenocarcinoma Mouse Increase levels [11]
MMP-2 Articular chondrocytes Rabbit Increase levels
Activation [12]
MMP-2 Mesangial cells Rat Activation [13]
MMP-3 Articular chondrocytes Rabbit Increase levels [14]
MMP-3 Cartilage Bovine, human Activation [6]
MMP-8 Neutrophils Human Activation [15]
MMP-9 Articular chondrocytes Rabbit Activation [12, 14]
MMP-9 Mesangial cells Rat Reduced cytokine-
induced expression [16]
MMP-9 Aortic smooth muscle cells Rat Decrease levels [17]
MMP-9 Placental Human Activation [18]
MMP-13 Vascular endothelium Bovine Increase levels
Activation This study
MT1-MMP Articular chondrocytes Rabbit Activation [14]
chain reaction (RT-PCR) reagents were from Gibco cDNA products were electrophoresed in 1% agarose
and visualized with ethidium bromide staining. To con-(Gaithersburg, MD, USA), except from Taq DNA poly-
merase, which was from Applied Biosystems (Foster firm the specificity of the identity of the fragments ampli-
fied, PCR products were hybridized with the entireCity, CA, USA). Radio-labeled nucleotides were from
New England Nuclear (Boston, MA, USA). RNAase MMP-13 cDNA as a probe in Southern blot experiments.
inhibitor RNAsin, Dual Luciferase Reporter System,
Transient transfection of BAECpGL3 plasmids, and restriction endonucleases were from
Promega (Madison, WI, USA). Autoradiography film Bovine aortic endothelial cells plated in gelatin-coated
six-well plates were transiently transfected by a lipo-was from Kodak (Eastman Kodak, Rochester, NY,
USA). Polyvinylidine difluoride (PVDF) protein trans- some-mediated method using Lipofectamine reagent ac-
cording to the manufacturer’s standards.fer membranes were from Millipore (Millipore, Iberica,
Madrid, Spain), and the enhanced chemiluminescence Plasmid pCol3-WT contains a functional part of the
5 regulatory region of the human MMP-13 (Genbank(ECL) detecting immunoblot system was from Amer-
sham-Pharmacia (Buckinghamshire, UK). Transfection accesion no: NM_002427) into the KpnI/Bgl II restriction
sites of pGL3 basic. MMP-13 promoter activity was mea-reagents Optimem and Lipofectamine were from Gibco-
BRL. MMP-13 polyclonal antibodies were from Calbio- sured by the activity of a luciferase reporter located
downstream of the human MMP-13 promoter sequence.chem (CN Biosciences, Nottingham, UK); horseradish
peroxidase (HRP)-conjugated secondary antibodies were To check transfection efficiency, we performed the ex-
periments using the Dual Luciferase Reporter system,from DAKO (DAKO Diagnostics, Barcelona, Spain).
and co-transfecting BAEC with a pGL3 reporter plasmid
RNA isolation and RT-PCR expressing Renilla under the control of a CMV promoter
(pCMV-Renilla).Total RNA from BAEC was isolated by the guanidi-
nium thiocyanate method as described [27].
Immunoblot analysisFor RT-PCR experiments, cDNA was synthesized with
1 g of total RNA primed with random hexamer oligonu- Bovine aortic endothelial cells were disrupted in pro-
tein lysis buffer (50 mmol/L Tris-HCl, 1 mmol/L ethylene-cleotides, and incubated for one hour at 42C, in a reverse
transcription assay. For the subsequent PCR amplifica- diaminetetraacetic acid (EDTA), 1 mmol/L ethylene
glycol-bis(beta-aminoethyl ether)-N,N,N,N-tetraacetiction, the following primers based on the human MMP-13
mRNA were selected: sense primer, 5-CCAAATTAT acid (EGTA), 0.2 g/mL phenylmethylsulfonyl fluoride
(PMSF), and 2 g/mL of the protease inhibitors leupep-GGAGGAGATGC-3; antisense primer, 5-CGCCAG
AAGAATCTGTCTTTAAA-3. The amplification was tin, pepstatin, antipain, and antitrypsin). The homo-
genate wasbriefly centrifuged and supernatants wereperformed with 30 cycles consisting of denaturation for
30 seconds at 94C, primer annealing for 30 seconds at collected. Samples were quantified and stored for subse-
quent analysis.55C, and primer extension for 30 seconds at 72C. The
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Homogenates were fractionated by sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE),
and then transferred to PVDF membranes. MMP-13 pro-
tein expression was detected by incubating the mem-
branes with anti-MMP-13 [diluted 1:1000 in 3% bovine
serum albumin (BSA)]. Membranes were washed and
incubated with conjugated horseradish peroxidase–anti-
rabbit secondary antibodies, and developed with the
ECL, according to the manufacturer’s instructions.
Metalloproteinase activity
Matrix metalloproteinase-13 activity was measured by
using a commercial assay kit from Chemicon (Temecula,
CA, USA). In brief, samples were incubated with a fluo-
rescence substrate at room temperature, reactions were
stopped, and then the fluorescence of intensity as a
result of MMP-13 digestion was measured. Excitation
wavelength was at 340 nm. Emission wavelength was at
440 nm.
RESULTS
To elucidate if NO could induce MMP-13 expression
in BAEC, we exogenously administered NO by adding
DEA-NO (100 mol/L) or SNAP (100 mol/L), and as-
sayed MMP-13 expression by RT-PCR. Our first obser-
vation was that BAEC express a basal level of MMP-13
mRNA, which could be modulated by the addition of
DEA-NO. Transient transfection of BAEC with the hu-
man MMP-13 promoter region demonstrated that at
least in part, the NO-driven MMP-13 expression could
take place at the transcriptional level, and may be medi-
ated through the cGMP pathway (Fig. 1).
On the other hand, Western blot analysis with specific
anti-MMP-13 antibodies also demonstrated that DEA-
NO, even at the lowest concentration, mediates the tran-
sition from the 59 kD pro-MMP-13 to the 48 kD active
form in BAEC (Fig. 2). This process has been shown to
occur in the context of MMP-13 activation.
In an effort to demonstrate if the DEA-NO–mediated
48 kD polypeptide displayed enzymatic activity, we per-
formed MMP-13 activity assays by using a fluorescent
MMP-13 substrate to test if cell extracts from BAEC
treated with DEA-NO could activate the pro-enzyme.
Results showed that DEA-NO induced MMP-13 activity
in a dose-dependent manner (Fig. 3).
Fig. 1. Matrix metalloproteinase (MMP)-13 expression is increased
upon induction with nitric oxide (NO) donors. (A) RT-PCR experi-
ments using specific MMP-13 oligonucleotides from BAEC induced
with DEA-NO (100 mol/L), SNAP (100 mol/L), and L-NAME (500
mol/L) for 16 hours. Bovine GAPDH was included as a control.
Results are representative of 4 independent experiments (mean  SD; NO (100 mol/L) for 16 hours. Single data points were normalized by
*P 0.05 vs. control). (B) Transient transfection experiments of BAEC co-transfecting with pCMV-Renilla. Values are represented as fold
with the human MMP-13 promoter. Cells were transiently transfected induction respect to pCol3-WT-transfected resting cells (N 3, mean
with pCol3-WT (), or pCol3-mAPI(), and stimulated with DEA- SD; P  0.05 vs. resting; details are in the Methods section).
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Fig. 2. DEA-NO promotes the proteolytic cleavage of pro-MMP-13.
BAEC were stimulated with DEA-NO at different concentrations and
cell extracts were resolved in 12% SDS-PAGE. MMP-13 was detected
by immunoblot with anti-MMP-13 antibodies. The arrowhead indicates
the 48 kD band corresponding to the MMP-13 active form. Results are
representative of 3 independent experiments. Details are in the Methods
section.
DISCUSSION
Fig. 3. DEA-NO activates MMP-13 in BAEC. Cell extracts from
BAEC stimulated with DEA-NO at different concentrations were sub-Our study shows that nitric oxide transcriptionally reg-
jected to an MMP-13 activity assay with a fluorescent polypeptide sub-ulates and activates MMP-13, a metalloproteinase involved
strate. Results are represented as fluorescence intensity of emission from
in several pathophysiological conditions from tissue de- the cleaved MMP-13 substrate after incubation with the cell extracts.
KMST-col3 is a keratinocyte cell line that constitutively expresses MMP-velopment to cancer [28, 29]. We present direct evidence
13, and included as a positive control (N  2, mean  SD; *P  0.05that NO is transcriptionally regulating MMP-13 through
vs. control; details are in the Methods section).
the cGMP signaling pathway. The human MMP-13 pro-
moter region contains an activator protein-1 (AP-1) re-
sponsive element, which has been shown to be essential
nitric oxide synthase (iNOS) isoform, producing rapidlyfor a correct expression of the gene in all the cell types
diffusing NO at concentrations [37] comparable to thosein which MMP-13 is expressed [30]. Therefore, we postu-
we used to stimulate MMP-13 expression in BAEC.late that the AP-1 site of the MMP-13 promoter is the
In conclusion, the data presented here are in agree-main target for the action of NO/cGMP signaling in
ment with the pro-angiogenic properties of NO in theendothelial cells.
vascular endothelium by activating MMP-13, a metallo-To facilitate cell trafficking through the vessel wall,
proteinase implicated in several angiogenic conditions.endothelial cells express MMPs at the cell surface, a
process required during several events related to angio-
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